 - Patients receiving any medications or substances that are strong inducersinhibitors or substrates of cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A45, cytochrome P450, family 2, subfamily C, polypeptide 9 CYP2C9, CYP2C8, or CYP2C19 are ineligible; as part of the enrollmentinformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product 